Key Highlights
- The clonoSEQ MRD test will feature in about 100 abstracts at the ASH 2026 meeting, including 27 oral presentations.
- Twenty biopharma-sponsored studies use clonoSEQ, with MRD as a primary endpoint in four and a secondary endpoint in 11.
- ASH 2026 takes place from 12 to 15 December 2026 in New Orleans.
- Research highlighted includes data from Phase 3 studies in multiple myeloma, including PERSEUS, AURIGA and BENEFIT.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company, announced on 18 November 2026 that its next-generation sequencing-based clonoSEQ test for measurable residual disease will be featured across about 100 abstracts at the 68th Annual Meeting of the American Society of Hematology. The meeting takes place from 12 to 15 December 2026 in New Orleans.
The company said the research reflects growing use of MRD assessment, which it describes as moving beyond measuring depth of response toward informing how therapies are developed and adapted.
Studies and Presentations
Across 20 unique biopharma-sponsored studies featuring clonoSEQ, MRD is used as a primary endpoint in four studies and a secondary endpoint in 11. The company said 27 of the abstracts will be oral presentations.
In multiple myeloma, data from the PERSEUS, AURIGA and BENEFIT Phase 3 studies are scheduled for presentation, while research from PERSEUS and IMMUNOPLANT addresses treatment strategies such as maintenance de-escalation and consolidation therapy.
Real-World Research
The announcement also referenced real-world research from the Icahn School of Medicine at Mount Sinai that uses clonoSEQ data to identify patient groups. The company describes such research as a way to support long-term management of patients with lymphoid malignancies.
The release does not present new efficacy data of its own, and the abstracts it lists are subject to the meeting’s presentation schedule.
Company Context
Adaptive describes its Business as translating the genetics of the adaptive immune system into clinical products. clonoSEQ is the company’s MRD assessment test, and the announcement presents the ASH program as evidence of its use across several haematological settings.
The company did not disclose Revenue expectations, test volumes or reimbursement developments in the announcement.
Final Word
Adaptive Biotechnologies has highlighted about 100 abstracts featuring clonoSEQ at ASH 2026, including 27 oral presentations and studies in which MRD is a primary or secondary endpoint. The company’s presence at the meeting is centred on research by other sponsors and institutions.
The abstracts are research presentations rather than regulatory decisions, and the announcement does not show how the findings will affect clonoSEQ’s commercial use. Subsequent company reporting will show whether the research results are reflected in test demand.






Please wait processing your request...